Publication: 4124

Publication: 4124

Alliance A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer

DOI

URL

Google Scholar

Citation:: Cancer Research vol 84 (9_Supplement) PO3-18-11

Meeting Instance:: SABCS 2023
Year:: 2024
Type:: Abstract
Sub type:: Poster General
Funding:: NCTN
Endpoint:: No-Endpoint
Analysis:: Trial-Description-Only
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: None

Program:: OGC
Primary Committee:: Breast
Sec. Committees:

Pharmas:: Seagen Inc
Grants:: U10CA180821, U10CA180882

Corr. Author:
Authors:: Ciara O'Sullivan Karla Ballman Linda McCall Tyler Zemla Anna Weiss Melissa Mitchell Victoria Blinder Nadine Tung William Irvin Jr Myounghee Lee Sailaja Kamaraju Matthew Goetz W. Fraser Symmans Virginia Borges Ian Krop Ann Partridge Lisa Carey

Networks:: LAPS-CO070, LAPS-CT018, LAPS-MA036, LAPS-MN026, LAPS-NC007, LAPS-NY016, LAPS-TX035, LAPS-WI013, MD015, NY167, SCOR

Study: Alliance-A011801
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: